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Wider lessons of the pulmonary artery catheter trial
Intensivists are rising to the challenge of evaluating established practices
Although we demand rigorous scrutiny of thesafety and efficacy of new products, clinicianshave been slow to evaluate existing practices.
This may be human nature—most clinicians pay lip
service to the need to scrutinise and optimise current
practice but generally believe it is others’ practice, and
not their own, that is suboptimal. Consequently, obser›
vational studies that show differences in outcomes
associated with variation in practice are only rarely fol›
lowed by randomised trials. A trial soon to get
underway in British intensive care units is one such
exception: from it, the rest of medicine may be able to
learn much about having the courage to look within
and to seek to practise better medicine.
One reason why it is hard to question existing
practice is that clinicians often feel it is unethical to
submit a particular aspect of their practice to randomi›
sation, irrespective of the evidence against that
practice. But with such a position, how can we ever
progress? What is the ethical difference between deny›
ing a patient in the control arm of a clinical trial a new,
as yet unapproved and unproved, treatment and deny›
ing her an established treatment of uncertain value?
The solution is to be committed to more rigorous
evaluation of current practice. That means certain
established interventions must be evaluated further.
And there lies the rub: a clinician, regardless of
personal belief, must be prepared to enrol patients in
trials where existing treatments will be denied to
randomly selected patients. An example of such a
process was the United Kingdom extracorporeal
membrane oxygenation (ECMO) collaborative trial in
neonates.1 This intervention was already available
when the trial started, though not to all babies.
Although virtually every neonatologist in the United
Kingdom had a strong opinion on its value, there was
no consensus. The neonatologists gathered together,
suspending personal beliefs and practice styles, to con›
duct a landmark randomised controlled trial which
showed convincingly the importance of regional
centres for extracorporeal membrane oxygenation.
But in that trial patients were randomised to be trans›
ferred to different hospitals, thus avoiding the need for
individual doctors to treat the neonates under their
own care in different ways.
A much greater challenge is the UK pulmonary
artery catheter management trial. The pulmonary
artery catheter has been the mainstay of haemo›
dynamic monitoring and management of critically ill
patients for the past 30 years, but recent data from
observational studies suggest the catheter may be of
questionable benefit and potentially cause harm
(FN MacKirdy et al, Intensive Care Society scientific
meeting, May 1997).2 Although it is a diagnostic tool,
there are a series of haemodynamic manipulations that
clinicians may use in response to readings from a pul›
monary artery catheter. Harm may result, therefore,
both from inexpert placement of the catheter and inju›
dicious choice of therapies in response to readings
from the catheter.
British intensive care units have huge variations in
pulmonary artery catheter use, with insertion rates
varying from 3% to 76% of admissions (K Rowan, per›
sonal communication). If the pulmonary artery
catheter does indeed influence mortality, the number
of lives lost or saved due either to inappropriate use or
to lack of use could be staggering. In response, the
British adult intensive care community has gathered
together to conduct a randomised trial of pulmonary
artery catheter use. More than one third of all intensive
care units in the United Kingdom are participating in
this 6000 patient trial. The heart of the study is the
intensive care community’s commitment to examine
and improve practice.
In every participating intensive care unit clinicians
must subject their personal management style to
randomisation. This is not trivial. Consider a patient
randomised not to receive a pulmonary artery catheter
yet cared for by a clinician who believes she provides
better care using that catheter. She must continually
remind herself that her existing beliefs are not
supported by strong scientific evidence—and her man›
agement of the current patient, without the pulmonary
artery catheter, must continue. To stay the course will
force many clinicians to face many demons. They will
learn much about themselves, the way in which they
appraise evidence, and the way in which they develop
and maintain their practice style.
Despite the large size of the trial, the large number
of participating units will allow this study to be
completed in 12 months. This act of solidarity will
bring crucial evidence to bear on a problem that has
been debated worldwide for decades. It is the perfect
example of commitment to greater scrutiny and
optimisation of practice that we must all engage in,
across all fields of medicine.
The UK pulmonary artery catheter management
trial is a challenge—a challenge to all of medicine. It
asks us to have the courage to look within, to examine
ourselves, and to seek to be better. Regardless of the
fate of the pulmonary artery catheter, the greatest tes›
tament to the intensive care community will be their
ability to complete the trial. And with its completion we
look forward to similar trials of established but
unproved treatments in other areas of medicine. For
only with such commitment can clinicians truly make
the statement that they seek to provide optimal care.
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